Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02232269
Other study ID # R-11-655
Secondary ID NA-7122
Status Completed
Phase Phase 1
First received
Last updated
Start date February 2012
Est. completion date May 2013

Study information

Verified date August 2018
Source Lawson Health Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Coffee is a globally popular beverage. More than half of the United States population spends an estimated $ 40 billion on the purchase of coffee each year. Personal consumption habits can vary. For example, the frequency of ingestion ranged from 59% for every day to 8% for less than one day per week consumption in one survey. In the case of occasional consumption, coffee can markedly elevate blood pressure in normotensive and hypertensive individuals. This pressor effect can occur with a caffeine dose of 200 - 250 mg, which can be found 2 - 3 cups of coffee. A major active constituent in coffee is caffeine, which is the most widely used pharmacological substance in the world.

Drug therapy plays a major role in the management of hypertension. However, the interaction between coffee or caffeine and blood pressure lowering drugs has been assessed in only three clinical studies that were reported more than three decades ago.

We conducted a comprehensive interaction study involving a commonly ingested amount of a particular Colombian coffee and felodipine in healthy middle-aged men and women. Peripheral (brachial) and central (aortic) hemodynamics and caffeine and felodipine pharmacokinetics were evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date May 2013
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria:

- healthy (normal physical exam, blood clinical chemistry)

- willingly signs ethics approved informed consent form

Exclusion Criteria:

- history of cardiac, renal, hepatic or gastrointestinal disease or substance abuse

- significant illness within 2 weeks of starting study

- history of allergy to felodipine , tablet ingredients or dihydropyridines

- routinely taking prescription or OTC drugs or natural health products

- received an investigational drug withing the previous 4 weeks

- females who are pregnant or breast-feeding

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Black Coffee

Grapefruit Juice

Water

Drug:
Felodipine


Locations

Country Name City State
Canada Victoria Clinical Trials Centre London Ontario

Sponsors (1)

Lead Sponsor Collaborator
Lawson Health Research Institute

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Bailey DG, Dresser GK, Urquhart BL, Freeman DJ, Arnold JM. Coffee-Antihypertensive Drug Interaction: A Hemodynamic and Pharmacokinetic Study With Felodipine. Am J Hypertens. 2016 Dec 1;29(12):1386-1393. doi: 10.1093/ajh/hpw081. — View Citation

Dresser GK, Urquhart BL, Proniuk J, Tieu A, Freeman DJ, Arnold JM, Bailey DG. Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. Pharmacol Res Perspect. 2017 Oct;5(5). doi: 10.1002/prp2.346. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The effect of felodipine on coffee-mediated increases in peripheral and central blood pressure . Peripheral (brachial systolic and diastolic blood pressure) and central (aortic systolic blood pressure) measurements were the mean of at least 3 readings after 5 minutes of sitting at rest. The respective instruments used were BpTRU™ Vital Signs Monitor (BpTRU Medical Devices, Coquitlam BC, Canada) and SphygmoCor® CP Pulse Wave Analysis System - Research (AtCor Medical, Inc., Itasca, IL USA). Change from Baseline to 8 hours Post Dose
Secondary The effect of coffee on the oral pharmacokinetics of felodipine. Area Under Curve (AUC) Time Frame: predose, 1,2,3,4,5,6,7,8 hours post-dose Change from Baseline to 8 hours Post Dose
See also
  Status Clinical Trial Phase
Completed NCT02848430 - Hop Botanical Dietary Supplements - Metabolism and Safety in Women N/A